非常早期的莱沃多巴可能会在莱什-尼汉病中预防自我伤害
Jasper E Visser1, Odelia Chorin2, H A Jinnah3
1Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands; Faculty of Science, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Neurology, Amphia Hospital, Breda, The Netherlands.
Pediatric neurology
|April 23, 2024
概括
早期的勒沃多巴治疗可以防止莱什-尼汉病 (LND) 的自我伤害. 这种在婴儿期开始的多巴胺替代疗法在预防LND患者的标志性自我伤害行为方面显示出有希望的结果.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 莱什-尼汉病 (LND) 的特点是多巴胺缺乏,导致幼儿期的 dystonia 和自我伤害.
- 之前在老年LND患者中进行多巴胺替代治疗的尝试取得了有限的成功.
- 一个假设表明,早期的多巴胺干预可能会阻止LND表型的充分发展.
研究的目的:
- 研究早期莱沃多巴治疗在患有莱什-尼汉病的婴儿中预防自我伤害和 dystonia 的疗效.
- 为了评估婴儿期开始的勒沃多巴治疗对LND患者的长期结果.
主要方法:
- 三名LND患者在11-13个月大时接受了莱沃多巴/卡比多巴治疗,剂量升级.
- 治疗包括监测 dystonia 严重程度和自我伤害的发生.
- 进行了一项文献审查,以比较自我伤害发病的年龄与报告的病例.
主要成果:
- 三名患者中有两名,现在是青少年,似乎已经免受自我伤害的保护,这是他们HPRT1基因突变的常见结果.
- 第三位患者在1.5岁时开始自我伤害,同时服用较低的利沃多巴剂量.
- 勒沃多巴对 dystonia 严重性的确切影响尚未确定.
结论:
- 早期和足够剂量的利沃多巴可以预防莱什-尼汉病的自我伤害.
- 对于LND患者,应尽早考虑服用利沃多巴,最好是在自我伤害开始之前.
- 需要进一步的研究来证实勒沃多巴的疗效,优化治疗时间和对LND的剂量.
相关概念视频
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:15Parkinson's Disease: Overview
537
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
537
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
01:28Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
01:37Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K